Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
3. Results
4. Toxicity Subtypes
4.1. Pruritus
4.2. Eczematous Lesions
4.3. Maculopapular Reaction
4.4. Alopecia
4.5. Vitiligo-like Lesions
4.6. Lichenoid Reactions
4.7. Other Less Common cAEs to CDK4/6i
4.8. Clinical Predictors of Cutaneous Toxicities
5. Discussion
6. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Malumbres, M. Cyclin-dependent kinases. Genome Biol. 2014, 15, 122. [Google Scholar] [CrossRef] [Green Version]
- O’Leary, B.; Finn, R.S.; Turner, B.O.N.C. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol. 2016, 13, 417–430. [Google Scholar] [CrossRef] [PubMed]
- Finn, R.S.; Crown, J.P.; Lang, I.; Boer, K.; Bondarenko, I.M.; Kulyk, S.O.; Ettl, J.; Patel, R.; Pinter, T.; Schmidt, M.; et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 2015, 16, 25–35. [Google Scholar] [CrossRef]
- Cristofanilli, M.; Turner, N.C.; Bondarenko, I.; Ro, J.; Im, S.-A.; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016, 17, 425–439, Erratum in Lancet Oncol. 2016, 17, e136; Erratum in Lancet Oncol. 2016, 17, e270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hortobagyi, G.N.; Stemmer, S.M.; Burris, H.A.; Yap, Y.-S.; Sonke, G.S.; Paluch-Shimon, S.; Campone, M.; Blackwell, K.L.; André, F.; Winer, E.P.; et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N. Engl. J. Med. 2016, 375, 1738–1748, Erratum in N. Engl. J. Med. 2018, 379, 2582. [Google Scholar] [CrossRef]
- Goetz, M.P.; Okera, M.; Wildiers, H.; Campone, M.; Grischke, E.-M.; Manso, L.; André, V.A.M.; Chouaki, N.; Antonio, B.S.; Toi, M.; et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res. Treat. 2021, 186, 417–428. [Google Scholar] [CrossRef] [PubMed]
- Olazagasti, C.; Lee, C.-S.; Liu, A.; Stefanov, D.; Cheng, K. A deep dive into CDK4/6 inhibitors: Evaluating real world toxicities and treatment paradigms in the elderly population. J. Oncol. Pharm. Pract. 2021, 29, 14–21. [Google Scholar] [CrossRef] [PubMed]
- Desnoyers, A.; Nadler, M.B.; Kumar, V.; Saleh, R.; Amir, E. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis. Cancer Treat. Rev. 2020, 90, 102086. [Google Scholar] [CrossRef]
- Raschi, E.; Fusaroli, M.; Ardizzoni, A.; Poluzzi, E.; De Ponti, F. Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. Cancers 2021, 13, 1758. [Google Scholar] [CrossRef]
- Onesti, C.E.; Jerusalem, G. CDK4/6 inhibitors in breast cancer: Differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev. Anticancer Ther. 2020, 21, 283–298. [Google Scholar] [CrossRef]
- Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer 2009, 9, 153–166. [Google Scholar] [CrossRef]
- Raschi, E.; Fusaroli, M.; La Placa, M.; Ardizzoni, A.; Zamagni, C.; Poluzzi, E.; De Ponti, F. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. Am. J. Clin. Dermatol. 2021, 23, 247–255. [Google Scholar] [CrossRef] [PubMed]
- Silvestri, M.; Cristaudo, A.; Morrone, A.; Messina, C.; Bennardo, L.; Nisticò, S.P.; Mariano, M.; Cameli, N. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review. Drug Saf. 2021, 44, 725–732. [Google Scholar] [CrossRef] [PubMed]
- Chawla, S.; Hill, A.; Fearfield, L.; Johnston, S.; Parton, M.; Heelan, K. Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: A single-centre experience. Breast Cancer Res. Treat. 2021, 188, 535–545. [Google Scholar] [CrossRef] [PubMed]
- Sharaf, B.; AlMasri, R.; Abdel-Razeq, N.; Salama, O.; Hamad, I.; Abunasser, M.; Abdel-Razeq, H. Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review. Clin. Cosmet. Investig. Dermatol. 2022, ume 15, 5–10. [Google Scholar] [CrossRef]
- Sollena, P.; Nikolaou, V.; Soupos, N.; Kotteas, E.; Voudouri, D.; Stratigos, A.J.; Fattore, D.; Annunziata, M.C.; Orlandi, A.; Di Nardo, L.; et al. Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors. Breast Cancer Res. Treat. 2020, 185, 247–253. [Google Scholar] [CrossRef] [PubMed]
- Available online: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf (accessed on 19 March 2020).
- Lasheen, S.; Shohdy, K.S.; Kassem, L.; Abdel-Rahman, O. Fatigue, alopecia and stomatitis among patients with breast cancer re-ceiving cyclin-dependent kinase 4 and 6 inhibitors: A systematic review and meta-analysis. Expert Rev. Anticancer Ther. 2017, 17, 851–856. [Google Scholar] [CrossRef]
- Pasqualoni, M.; Orlandi, A.; Palazzo, A.; Garufi, G.; Cannizzaro, M.C.; Pontolillo, L.; Pannunzio, S.; Cutigni, C.; Sollena, P.; Federico, F.; et al. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: Two cases of premature interruption of therapy and exceptional response. Front. Oncol. 2023, 13, 1067264. [Google Scholar] [CrossRef]
- Braal, C.L.; Jongbloed, E.M.; Wilting, S.M.; Mathijssen, R.H.J.; Koolen, S.L.W.; Jager, A. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. Drugs 2020, 81, 317–331. [Google Scholar] [CrossRef]
- Sibaud, V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am. J. Clin. Dermatol. 2018, 19, 345–361. [Google Scholar] [CrossRef]
- Goel, S.; DeCristo, M.J.; McAllister, S.S.; Zhao, J.J. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends Cell Biol. 2018, 28, 911–925. [Google Scholar] [CrossRef] [PubMed]
- Goel, S.; DeCristo, M.J.; Watt, A.C.; BrinJones, H.; Sceneay, J.; Li, B.B.; Khan, N.; Ubellacker, J.M.; Xie, S.; Metzger-Filho, O.; et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 2017, 548, 471–475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deng, J.; Wang, E.S.; Jenkins, R.W.; Li, S.; Dries, R.; Yates, K.; Chhabra, S.; Huang, W.; Liu, H.; Aref, A.R.; et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018, 8, 216–233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schaer, D.A.; Beckmann, R.P.; Dempsey, J.A.; Huber, L.; Forest, A.; Amaladas, N.; Li, Y.; Wang, Y.C.; Rasmussen, E.R.; Chin, D.; et al. The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Rep. 2018, 22, 2978–2994. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Bu, X.; Wang, H.; Zhu, Y.; Geng, Y.; Nihira, N.T.; Tan, Y.; Ci, Y.; Wu, F.; Dai, X.; et al. Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance. Nature 2018, 553, 91–95. [Google Scholar] [CrossRef] [Green Version]
- Ettl, T.; Schulz, D.; Bauer, R.J. The Renaissance of Cyclin Dependent Kinase Inhibitors. Cancers 2022, 14, 293. [Google Scholar] [CrossRef]
- Ferreira, M.N.; Ramseier, J.Y.; Leventhal, J.S. Dermatologic conditions in women receiving systemic cancer therapy. Int. J. Women’s Dermatol. 2019, 5, 285–307. [Google Scholar] [CrossRef]
- Behbahani, S.; Geisler, A.; Kolla, A.; Dreker, M.R.; Kaunitz, G.; Pomeranz, M.K. Art of prevention: The importance of dermatologic care when using aromatase inhibitors. Int. J. Women’s Dermatol. 2021, 7, 769–773. [Google Scholar] [CrossRef]
- Saggar, V.; Wu, S.; Dickler, M.N.; Lacouture, M.E. Alopecia with Endocrine Therapies in Patients with Cancer. Oncologist 2013, 18, 1126–1134. [Google Scholar] [CrossRef] [Green Version]
- Freites-Martinez, A.; Shapiro, J.; Chan, D.; Fornier, M.; Modi, S.; Gajria, D.; Dusza, S.; Goldfarb, S.; Lacouture, M.E. Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer. JAMA Dermatol. 2018, 154, 670–675. [Google Scholar] [CrossRef]
- Freites-Martinez, A.; Shapiro, J.; Hurk, C.V.D.; Goldfarb, S.; Jimenez, J.J.; Rossi, A.M.; Paus, R.; Lacouture, M.E. Hair disorders in cancer survivors. J. Am. Acad. Dermatol. 2018, 80, 1199–1213. [Google Scholar] [CrossRef] [PubMed]
- Zarkavelis, G.; Kollas, A.; Kampletsas, E.; Vasiliou, V.; Kaltsonoudis, E.; Drosos, A.; Khaled, H.; Pavlidis, N. Aromatase inhibitors induced autoimmune disorders in patients with breast cancer: A review. J. Adv. Res. 2016, 7, 719–726. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Andrew, P.; Valiani, S.; MacIsaac, J.; Mithoowani, H.; Verma, S. Tamoxifen-associated skin reactions in breast cancer patients: From case report to literature review. Breast Cancer Res. Treat. 2014, 148, 1–5. [Google Scholar] [CrossRef] [PubMed]
- Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239–245. [Google Scholar] [CrossRef] [PubMed]
Patient No./Sex/Age | Oncologic Therapy | Type of cAE, Reaction1/Reaction2/Reaction3/Reaction4 | Months of CDK4/6i Treatment at cAE Diagnosis, Reaction1/2/3/4, No. | Treatment cAE 1 | Treatment cAE 2 | 3 | 4 | Systemic Treatment | Outcome cAE1 | Outcome cAE2 | Outcome cAE3 | Outcome cAE 4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1/F/63 | Palbociclib | Pruritus/maculopapular rash/vitiligo | 8/10/12 | high potency steroid cream | high potency steroid cream | high potency steroid cream | none | PR | PR | NR | ||
2/F/79 | Ribociclib+letrozole | Pruritus/vitiligo | 6/16 | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | none | PR | PR | ||||
3/F/66 | Ribociclib+fulvestrant | Vitiligo | 6 | high potency steroid cream+calcineurin inhibitors | UVA/UVB phototherapy | PR | ||||||
4/F/54 | Ribociclib+fulvestrant | Pruritus/vitiligo/maculopapular rash | 8/8/9 | high potency steroid cream | high potency steroid cream | high potency steroid cream | UVA/UVB phototherapy | CR | PR | CR | ||
5/F/48 | Ribociclib+letrozole | Pruritus/maculopapular rash /vitiligo | 4/4/6 | high potency steroid cream+emollient cream | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | none | PR | CR | NR | ||
6/F/73 | Ribociclib+letrozole | Pruritus/maculopapular rash /vitiligo | 4/8/16 | high potency steroid cream+antihistamine cream | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | none | PR | CR | NR | ||
7/F/59 | Ribociclib+letrozole | Pruritus/maculopapular rash /vitiligo | 6/10/12 | high potency steroid cream | high potency steroid cream | high potency steroid cream | none | PR | PR | PR | ||
8/F/56 | Ribociclib+letrozole | Pruritus/eczematous rash/alopecia | 4/5/7 | high potency steroid cream | high potency steroid cream | minoxidil | steroid | PR | PR | PR | ||
9/F/50 | Ribociclib+letrozole | Pruritus/asteatosis/eczematous rash | 5/6/8 | high potency steroid cream | high potency steroid cream+emollient cream | high potency steroid cream+emollient cream | none | CR | CR | PR | ||
10/F/68 | Ribociclib+letrozole | Pruritus/asteatosis/vitiligo | 4/7/9 | high potency steroid cream+antihistamine cream | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | none | CR | CR | PR | ||
11/F/64 | Ribociclib+letrozole | Pruritus/Papulo-pustular rash | 7/8 | combo steroid+antiseptic/antibiotic cream | combo steroid+antiseptic/antibiotic cream | antibiotic | CR | CR | ||||
12/F/82 | Ribociclib+letrozole | Pruritus/eczematous rash | 8/12 | high potency steroid cream | high potency steroid cream | none | PR | PR | ||||
13/F/63 | Ribociclib+letrozole | Pruritus/alopecia/maculopapular rash | 6/9/11 | high potency steroid cream | high potency steroid cream | high potency steroid cream+emollient cream | none | PR | CR | CR | ||
14/F/63 | Ribociclib+letrozole | Pruritus/eczematous rash /vitiligo | 5/6/10 | high potency steroid cream | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | none | PR | PR | NR | ||
15/F/68 | Ribociclib+fulvestrant | Pruritus/Lichenoid reaction | 5/7 | high potency steroid cream | high potency steroid cream | steroid | CR | CR | ||||
16/F/69 | Ribociclib+letrozole | alopecia | 6 | minoxidil | none | PR | ||||||
17/F/65 | Ribociclib+letrozole | alopecia | 11 | minoxidil | none | PR | ||||||
18/F/59 | Abemaciclib | Pruritus/Lichenoid reaction/alopecia | 5/9/12 | high potency steroid cream | high potency steroid cream | minoxidil | none | PR | PR | NR | ||
19/F/61 | Ribociclib+letrozole | Pruritus/ maculopapular rash | 6/8 | high potency steroid cream | high potency steroid cream | none | PR | CR | ||||
20/F/56 | Ribociclib+letrozole | Nail dystrophy/alopecia | 5/8 | combo steroid+antiseptic/antibiotic cream | minoxidil | antibiotic | PR | PR | ||||
21/F/42 | Ribociclib+letrozole | Pruritus/ maculopapular rash | 4/4 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
22/F/77 | Ribociclib+letrozole | Pruritus/ maculopapular rash | 7/8 | high potency steroid cream | high potency steroid cream | steroid | CR | CR | ||||
23/F/50 | Ribociclib+letrozole | alopecia | 5 | minoxidil | none | PR | ||||||
24/F/61 | Ribociclib+anastrazole | Pruritus/eczematous rash | 8/10 | high potency steroid cream | high potency steroid cream | none | PR | PR | ||||
25/F/76 | Ribociclib+letrozole | Pruritus/alopecia | 4/8 | high potency steroid cream | high potency steroid cream+minoxidil | none | PR | NR | ||||
26/F/72 | Ribociclib+letrozole | Pruritus/Cutaneous lupus | 3/5 | high potency steroid cream+emollient cream | high potency steroid cream+emollient cream | none | CR | PR | ||||
27/F/80 | Ribociclib+letrozole | Pruritus/eczematous rash/Hand and Foot reaction | ¾/14 | high potency steroid cream+emollient cream | high potency steroid cream+emollient cream | combo steroid+antiseptic/antibiotic cream | steroid | CR | CR | PR | ||
28/F/56 | Palbociclib+letrozole | Lichenoid reaction | 12 | emollient cream | none | PR | ||||||
29/F/44 | Palbociclib+letrozole | Pruritus/eczematous rash/papulopustular rash | 7/14/17 | high potency steroid cream | high potency steroid cream+metronidazole cream | combo steroid+antiseptic/antibiotic cream | antibiotic | PR | PR | CR | ||
30/M/46 | Ribociclib | Papulo-papulopustular rash | 1 | combo steroid+antiseptic/antibiotic cream | antibiotic | PR | PR | |||||
31/F/42 | Ribociclib+letrozole | Pruritus/vitiligo | 4/14 | mild steroid cream | mild steroid cream | UVA/UVB phototherapy | PR | NR | ||||
32/F/45 | Palbociclib+letrozole | Cutaneous lupus | 4 | mild steroid cream | mild steroid cream+calcineurin inhibitors | none | PR | |||||
33/F/60 | Ribociclib+letrozole | Pruritus/eczematous rash/alopecia | 4/7/10 | high potency steroid cream | high potency steroid cream | minoxidil | antihistamine | PR | PR | PR | ||
34/F/60 | Ribociclib+letrozole | eczematous rash/vitiligo | 8 | mild steroid cream | high potency steroid cream | none | CR | PR | ||||
35/F/64 | Ribociclib+fulvestrant | papulopustular rash/eczematous rash | 2/8 | mild steroid cream | mild steroid cream | steroid + antibiotic | CR | CR | ||||
36/F/67 | Ribociclib+letrozole | Pruritus/asteatosis | 5/8 | high potency steroid cream | emollient cream | none | PR | PR | ||||
37/F/63 | Ribociclib+letrozole | Vitiligo | 10 | high potency steroid cream+calcineurin inhibitors | none | NR | ||||||
38/F/68 | Ribociclib+letrozole | Pruritus/papulopustular rash /eczematous rash/vitiligo | 4/5/10/13 | high potency steroid cream | combo steroid+antiseptic/antibiotic cream | high potency steroid cream | high potency steroid cream | steroid | PR | PR | PR | PR |
39/F/72 | Ribociclib+fulvestrant | Pruritus/eczematous rash | 5/15 | high potency steroid cream | high potency steroid cream | steroid | CR | CR | ||||
40/F/39 | Ribociclib+letrozole | vitiligo | 11 | high potency steroid cream | UVA/UVB phototherapy | PR | ||||||
41/F/46 | Ribociclib+letrozole | alopecia | 8 | none | none | NR | ||||||
42/F/78 | Palbociclib+fulvestrant | alopecia | 9 | none | none | NR | ||||||
43/F/70 | Palbociclib+letrozole | Alopecia/eczematous rash | 10/12 | mild steroid cream | mild steroid cream | high potency steroid cream | none | PR | CR | |||
44/F/74 | Ribociclib+letrozole | Pruritus/psoriasis/alopecia/Vitiligo | 1/5/8/10 | high potency steroid cream | high potency steroid cream+combo steroid+antiseptic/antibiotic cream | minoxidil | high potency steroid cream+calcineurin inhibitors | none | PR | PR | CR | NR |
45/F/71 | Palbociclib+letrozole | alopecia | 6 | none | none | NR | ||||||
46/F/76 | Palbociclib+letrozole | alopecia | 7 | none | none | NR | ||||||
47/F/68 | Palbociclib+letrozole | alopecia | 5 | none | none | NR | ||||||
48/F/70 | Ribociclib+letrozole | eczematous rash/alopecia | 12/14 | mild steroid cream | minoxidil | none | PR | PR | ||||
49/F/73 | Palbociclib+fulvestrant | alopecia | 7 | minoxidil | none | PR | ||||||
50/F/83 | Ribociclib+letrozole | Pruritus/eczematous rash/Vitiligo | ¾/8 | high potency steroid cream | combo steroid+antiseptic/antibiotic cream | high potency steroid cream | antihistamine | PR | PR | NR | ||
51/F/54 | Palbociclib+letrozole | Alopecia/eczematous rash | 8/10 | minoxidil | high potency steroid cream | spironolactone | PR | CR | ||||
52/F/61 | Palbociclib+letrozole | Alopecia | 10 | minoxidil | none | CR | ||||||
53/F/52 | Ribociclib+letrozole | Eczematous rash/Alopecia | 14/18 | high potency steroid cream | minoxidil | none | PR | PR | ||||
54/F/58 | Palbociclib+letrozole | Pruritus/eczematous rash | 2/4 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
55/F/63 | Palbociclib+letrozole | Pruritus/eczematous rash | 2/3 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
56/F/59 | Palbociclib+fulvestrant | Pruritus/ maculopapular rash | 3/6 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
57/F/58 | Palbociclib+letrozole | Pruritus/ maculopapular rash | 4/5 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
58/F/51 | Palbociclib+letrozole | Pruritus/alopecia/Psoriasis | 5/6/10 | mild steroid cream | minoxidil | mild steroid cream | none | PR | PR | PR | ||
59/F/64 | Ribociclib+letrozole | Alopecia | 7 | minoxidil | spironolactone | PR | ||||||
60/F/67 | Palbociclib+letrozole | Pruritus/eczematous rash | 4/4 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
61/F/59 | Palbociclib+letrozole | Maculopapular rash | 2 | high potency steroid cream | none | CR | ||||||
62/F/68 | Palbociclib+letrozole | Pruritus/eczematous rash | 2/3 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
63/F/62 | Ribociclib+letrozole | Pruritus/maculopapular rash | 4/4 | high potency steroid cream | high potency steroid cream | none | CR | CR | ||||
64/F/56 | Ribociclib+letrozole | Pruritus/psoriasis | 4/6 | high potency steroid cream+emollient cream | high potency steroid cream+emollient cream | none | PR | PR | ||||
65/F/62 | Ribociclib+anastrazole | Pruritus/Alopecia/eczematous rash | 5/6/8 | mild steroid cream | minoxidil | mild steroid cream+emollient cream | none | PR | PR | PR | ||
66/F/46 | Ribociclib | Maculopapular rash/Alopecia | 5/8 | mild steroid cream | minoxidil | none | PR | PR | ||||
67/F/63 | Palbociclib+fulvestrant | Pruritus/Lichenoid reaction | 6/8 | high potency steroid cream | high potency steroid cream | none | PR | PR | ||||
68/F/80 | Ribociclib+letrozole | Vitiligo/maculopapular rash | 10/10 | high potency steroid cream+calcineurin inhibitors | high potency steroid cream | UVA/UVB phototherapy | PR | PR | ||||
69/F/58 | Ribociclib+letrozole | Pruritus/Vitiligo | 5/15 | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | UVA/UVB phototherapy | PR | PR | ||||
70/F/64 | Palbociclib+fulvestrant | Pruritus/eczematous rash | 7/9 | calcineurin inhibitors | high potency steroid cream | none | CR | CR | ||||
71/F/69 | Ribociclib+letrozole | lichenoid reaction/vitiligo | 8 | high potency steroid cream | high potency steroid cream | none | PR | PR | ||||
72/F/53 | Ribociclib+letrozole | Pruritus/Vitiligo | 4/8/9 | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | antihistamine | PR | PR | ||||
73/F/71 | Ribociclib+letrozole | Pruritus/lichenoid reaction /Vitiligo | 6/8/12 | high potency steroid cream | high potency steroid cream | high potency steroid cream+calcineurin inhibitors | none | PR | PR | NR | ||
74/F/55 | Ribociclib+letrozole | Pruritus/ maculopapular rash | 6/8 | emollient cream | emollient cream | none | CR | CR | ||||
75/F/49 | Ribociclib+letrozole | Pruritus/lichenoid reaction | 4/7 | high potency steroid cream | high potency steroid cream | none | PR | PR | ||||
76/F/66 | Palbociclib+letrozole | Asteatosis/Nail dystrophy | 2/6 | emollient cream | emollient cream+calcineurin inhibitors | none | CR | PR | ||||
77/F/68 | Palbociclib+fulvestrant | morphea | 3 | high potency steroid cream+calcineurin inhibitors | none | PR | ||||||
78/F/82 | Ribociclib+fulvestrant | Pruritus/maculopapular rash/Hand and Foot reaction | 2/4/6 | high potency steroid cream+antihistamine cream | high potency steroid cream+emollient cream | high potency steroid cream+emollient cream | none | CR | CR | PR | ||
79/F/47 | Ribociclib+examestane | Pruritus/eczematous rash/ acral hyperpigmentation/Nail dystrophy | ¼/8/12 | high potency steroid cream+antihistamine cream | high potency steroid cream+emollient cream | high potency steroid cream+emollient cream | high potency steroid cream+calcineurin inhibitors | none | PR | PR | PR | PR |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sollena, P.; Vasiliki, N.; Kotteas, E.; Stratigos, A.J.; Fattore, D.; Orlandi, A.; Mannino, M.; Di Pumpo, M.; Fida, M.; Starace, M.; et al. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study. Cancers 2023, 15, 3658. https://doi.org/10.3390/cancers15143658
Sollena P, Vasiliki N, Kotteas E, Stratigos AJ, Fattore D, Orlandi A, Mannino M, Di Pumpo M, Fida M, Starace M, et al. Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study. Cancers. 2023; 15(14):3658. https://doi.org/10.3390/cancers15143658
Chicago/Turabian StyleSollena, Pietro, Nikolaou Vasiliki, Elias Kotteas, Alexander J. Stratigos, Davide Fattore, Armando Orlandi, Maria Mannino, Marcello Di Pumpo, Monika Fida, Michela Starace, and et al. 2023. "Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study" Cancers 15, no. 14: 3658. https://doi.org/10.3390/cancers15143658